Know Cancer

or
forgot password

A Multicentre, Retrospective Chart Review Study to Characterise Gefitinib Usage and Outcomes in Routine Treatment


N/A
18 Years
N/A
Not Enrolling
Both
Lung Cancer

Thank you

Trial Information

A Multicentre, Retrospective Chart Review Study to Characterise Gefitinib Usage and Outcomes in Routine Treatment


A multicentre, retrospective chart review study to characterise gefitinib usage and outcomes
in routine treatment


Inclusion Criteria:



- Patients who received gefitinib first line in the UK Single Payment Access (SPA)
scheme

- Locally advanced or metastatic EGFR mutation positive NSCLC

- Supplied with first pack of gefitinib prior to 1st January 2012

Exclusion Criteria:

- Patient was treated privately (i.e. outside the NHS)

- Gefitinib was second-line therapy following treatment failure on a prior therapy

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Retrospective

Outcome Measure:

Assessment of treatment duration, as a surrogate of Clinical Benefit (CB) in a 'Real World' population treated with gefitinib

Outcome Description:

Retrospective population [2009 to 2013]

Outcome Time Frame:

6 months

Safety Issue:

No

Principal Investigator

Fiona Blackhall, MBCHB FRCP

Investigator Role:

Principal Investigator

Investigator Affiliation:

The Christie NHS Foundation Trust

Authority:

United Kindom: Not Applicable for Observational and Retrospective Study

Study ID:

NIS-OGB-IRE-2012/1

NCT ID:

NCT01818947

Start Date:

April 2013

Completion Date:

August 2013

Related Keywords:

  • Lung Cancer
  • Lung cancer
  • epidermal growth factor receptor mutation
  • gefitinib
  • Iressa
  • Lung Neoplasms

Name

Location